"An ~80% reduction in hsCRP achieved within the first week and maintained throughout 12 weeks," said CEO Raju Mohan, suggesting VTX3232 "holds promise for a new generation of oral anti-inflammatory therapies that, orthogonal to lipid lowering, may further reduce cardiovascular events." Ventyx is withholding development plans for "future disclosures" but is also exploring VTX3232 in an ongoing phase 2 Parkinson's disease study
doi: 10.1002/jnr.21483 34 HamiltonAPattersonSPorterDGaultVAHolscherC
The proposed mechanisms include upregulation of growth hormone receptors in fibroblasts, modulation of the nitric oxide (NO) system for enhanced angiogenesis (new blood vessel growth), and reduction of inflammatory cytokines
This amino acid produces more nitrous oxide, which increases the benefits throughout the body
PlexusDx offers oral tirzepatide at $349/mo month-to-month, or from $279/mo on the 6-month plan with the same personalized dosing approach as injections